What's Happening?
Oncolytics Biotech Inc., a clinical-stage immunotherapy company, has announced its decision to voluntarily delist from the Toronto Stock Exchange (TSX) effective August 22, 2025. The company will maintain its listing on the Nasdaq, where it trades under the symbol 'ONCY'. The decision to delist from the TSX is part of Oncolytics' strategic focus on its U.S. operations and shareholder base. The company is also considering re-domiciling to the U.S. in the future, as it will cease to be treated as a Foreign Private Issuer under U.S. federal securities laws starting January 1, 2026.
AD
Why It's Important?
Oncolytics' decision to delist from the TSX underscores a strategic shift towards consolidating its operations and investor relations in the U.S. market. This move could streamline regulatory compliance and reduce costs associated with maintaining a dual listing. For investors, the focus on Nasdaq may enhance liquidity and visibility in the U.S. market, potentially attracting more investment. The company's emphasis on U.S. operations aligns with its development goals for pelareorep, an immunotherapeutic agent, which has shown promise in cancer treatment.
What's Next?
Following the delisting, Oncolytics will continue to trade on the Nasdaq, and Canadian shareholders can trade their shares through U.S.-registered broker-dealer affiliates. The company will remain a reporting issuer in Canada, ensuring compliance with Canadian securities regulations. Oncolytics' potential re-domiciling to the U.S. will be a key development to watch, as it could further integrate the company into the U.S. biotech landscape.
